Author

Blake E. Tomkinson

Observed names: B E Tomkinson, B Tomkinson, Blake E Tomkinson, Blake Tomkinson

Institution: Kura Oncology (United States)

Observed institutions: The Royal Melbourne Hospital, Harvard University, University of Massachusetts Chan Medical School, University of Colorado Boulder, Walter and Eliza Hall Institute of Medical Research, Peter MacCallum Cancer Centre, University of Colorado System, Mount Sinai Medical Center, EMD Serono, Inc. (United States), Gilead Sciences (United States), Kura Oncology (United States), Merck Healthcare KGaA, Darmstadt (Germany)

OpenAlex ID: A5049130593

Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation

1993 · B Tomkinson, E Robertson, et al. · Journal of Virology · 388

Recombinant Epstein-Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates in vitro.

1991 · S Swaminathan, B Tomkinson, et al. · Proceedings of the National Academy of Sciences · 228

Activated lymphocytes during acute Epstein-Barr virus infection.

1987 · B E Tomkinson, D K Wagner, et al. · The Journal of Immunology · 185

Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa

1995 · E S Robertson, S Grossman, et al. · Journal of Virology · 166

Soluble CD8 during T cell activation.

1989 · B E Tomkinson, M C Brown, et al. · The Journal of Immunology · 159

Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro

1992 · B Tomkinson, E Kieff · Journal of Virology · 127

BHRF1, the Epstein-Barr virus gene with homology to Bc12, is dispensable for B-lymphocyte transformation and virus replication

1991 · A Marchini, B Tomkinson, et al. · Journal of Virology · 126

PDF

The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein 2 (LMP2) are dispensable for lymphocyte infection and growth transformation in vitro

1993 · R Longnecker, C L Miller, et al. · Journal of Virology · 117

Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B

1993 · R Longnecker, C L Miller, et al. · Journal of Virology · 99

PDF

Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

2022 · Harry P. Erba, Amir T. Fathi, et al. · Blood · 70

An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B lymphocytes in vitro

1994 · E S Robertson, B Tomkinson, et al. · Journal of Virology · 69

Epstein-Barr virus recombinants from overlapping cosmid fragments

1993 · B Tomkinson, E Robertson, et al. · Journal of Virology · 67

Characterization of the T cell-mediated cellular cytotoxicity during acute infectious mononucleosis.

1989 · B E Tomkinson, R Maziarz, et al. · The Journal of Immunology · 67

Preliminary Data on a Phase 1/2A First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

2020 · Eunice S. Wang, Jessica K. Altman, et al. · Blood · 64

Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan.

2000 · D L Emerson, R Bendele, et al. · PubMed · 61

Oligoclonal Expansion of Intraepidermal T Cells in Psoriasis Skin Lesions

2001 · David A. Norris, Brian L. Kotzin, et al. · Journal of Investigative Dermatology · 56

PDF

Second-site homologous recombination in Epstein-Barr virus: insertion of type 1 EBNA 3 genes in place of type 2 has no effect on in vitro infection

1992 · B Tomkinson, E Kieff · Journal of Virology · 56

PDF

OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL

2003 · Blake Tomkinson, Ray Bendele, et al. · Leukemia Research · 39

Polymerization of the triphosphates of AraC, 2′,2′-difluorodeoxycytidine (dFdC) and OSI-7836 (T-araC) by human DNA polymerase α and DNA primase

2004 · Katherine A. Richardson, Tanya P. Vega, et al. · Biochemical Pharmacology · 37

The Role of Human Nucleoside Transporters in Cellular Uptake of 4′-Thio-β-d-arabinofuranosylcytosine and β-d-Arabinosylcytosine

2006 · Marilyn L. Clarke, Vijaya L. Damaraju, et al. · Molecular Pharmacology · 33

Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice

2001 · John P Desjardins, Elizabeth A Abbott, et al. · Anti-Cancer Drugs · 18

ATX-MS-1467 Induces Long-Term Tolerance to Myelin Basic Protein in (DR2 × Ob1)F1 Mice by Induction of IL-10-Secreting iTregs

2018 · Adriano Luís Soares De Souza, Stefan Rudin, et al. · Neurology and Therapy · 13

PDF

Preclinical In Vivo Activity of the Menin Inhibitor Ziftomenib (KO-539) in Pediatric KMT2A-Rearranged Acute Lymphoblastic Leukemia

2022 · Catherine D Falkenstein, Lisa M Niswander, et al. · Blood · 8

APAL2020K/ITCC-101: A Phase I Trial of the Menin Inhibitor Ziftomenib in Combination with Chemotherapy in Children with Relapsed/Refractory KMT2A- rearranged , NUP98- rearranged , or NPM1- mutant Acute Leukemias

2024 · Elisabeth Salzer, Janine Stutterheim, et al. · Blood · 7

PDF

Phase 1 study of ziftomenib (KO-539) in combination with venetoclax or venetoclax/azacitidine or standard induction cytarabine/daunorubicin (7+3) chemotherapy for the treatment of patients with acute myeloid leukemia.

2023 · Amer Methqal Zeidan, Amir Tahmasb Fathi, et al. · Journal of Clinical Oncology · 7

Works count: 44

Citation count: 2,288

H-index: 20

I10-index: 22